Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 3/20 | 0.43 |
| ▸ | FYN | P06241 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | MAP4K4 | O95819 | 7/20 | 0.39 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.39 |
| ▸ | CARM1 | Q86X55 | 2/20 | 0.38 |
| ▸ | PRMT6 | Q96LA8 | 2/20 | 0.38 |
| ▸ | KDM1A | O60341 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3034191 | 0.99 | GRIN2B (0.42) | GRIN2BFYNHDAC1MAP4K4PRMT5 | |
| SCHEMBL3044397 | 0.91 | HDAC1 (0.46) | GRIN2BFYNHDAC1PRMT5DRD2 | |
| SCHEMBL13137266 | 0.85 | GRIN2B (0.40) | GRIN2BFYNHDAC1PRMT5DRD2 | |
| SCHEMBL13137081 | 0.85 | MAP4K4 (0.50) | MAP4K4CARM1PRMT6 | |
| SCHEMBL13137147 | 0.84 | GRIN2B (0.39) | GRIN2BFYNHDAC1PRMT5 | |
| Hydrochloric Acid SCHEMBL3047248 | 0.84 | GRIN2B (0.39) | GRIN2BFYNHDAC1PRMT5DRD2 | |
| Hydrochloric Acid SCHEMBL3053348 | 0.84 | MAP4K4 (0.49) | MAP4K4CARM1PRMT6 | |
| SCHEMBL13137128 | 0.84 | OPRM1 (0.37) | GRIN2BFYNHDAC1PRMT5 | |
| SCHEMBL13137158 | 0.84 | GRIN2B (0.37) | GRIN2BFYNHDAC1PRMT5 | |
| SCHEMBL13137135 | 0.84 | ALOX5AP (0.41) | GRIN2BFYNHDAC1PRMT5DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100222345-A1 | NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS FOR OPIOID RECEPTORS | SMITHKLINE BEECHAM CORPORATION | 2010-09-02 | — | — | US | claimed |
| US-20100222345-A1 | NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS FOR OPIOID RECEPTORS | SMITHKLINE BEECHAM CORPORATION | 2010-09-02 | — | — | US | disclosed |
| US-20100222345-A1 | NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS FOR OPIOID RECEPTORS | SMITHKLINE BEECHAM CORPORATION | 2010-09-02 | — | — | US | disclosed |
| US-20100222345-A1 | NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS FOR OPIOID RECEPTORS | SMITHKLINE BEECHAM CORPORATION | 2010-09-02 | — | — | US | disclosed |
| WO-2008021851-A2 | NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS FOR OPIOID RECEPTORS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222345-A1 | NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS FOR OPIOID RECEPTORS | OPRL1, OPRM1, OPRK1 | GRIN2B 148/4885FYN 2222/4885HDAC1 2221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.